Page last updated: 2024-12-06

levamisole hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Levamisole hydrochloride is a synthetic antiparasitic drug that was originally developed to treat parasitic infections in animals. It is also used as an immunomodulator in humans. Levamisole hydrochloride is a chiral molecule, with the levorotatory isomer being the active enantiomer. The compound is typically synthesized via a multi-step process involving the reaction of 2-amino-5-chloro-benzaldehyde with 2-methyl-2,3-diaminobutane. Levamisole hydrochloride exerts its effects by stimulating the immune system, particularly the activity of natural killer cells. It has been shown to have anti-inflammatory, anti-cancer, and anti-viral properties. Due to its immunomodulatory effects, levamisole hydrochloride has been investigated for its potential use in treating various conditions, including cancer, autoimmune diseases, and viral infections. However, its use is controversial due to its potential for adverse effects, including agranulocytosis (a potentially life-threatening decrease in white blood cell count), and neurotoxicity. Research on levamisole hydrochloride continues to explore its potential therapeutic applications and its mechanisms of action, with an emphasis on understanding and mitigating its potential side effects.'

Cross-References

ID SourceID
PubMed CID27944
CHEMBL ID1770
CHEBI ID6433
SCHEMBL ID19226
MeSH IDM0330203

Synonyms (169)

Synonym
MLS002153440
smr001230807
ergamisol
kw-2299
r-12,564
levacide
spartakon
levasole
(-)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride
levadin
imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (-)-
solaskil
einecs 240-654-6
ripercol-l
levomysol hydrochloride
citarin l
worm-chek
imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, l-(-)-
kw-2-le-t
dekaris
meglum
kw 2le-t
ascaridil
nemicide
levamisole hydrochloride [usan]
nilverm forte
imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (s)-
l-(-)-2,3,5,6-tetrahydro-6-phenyl-imidazo(2,1-b)thiazole hydrochloride
EU-0100690
(-)-tetramisole hydrochloride, >=99% (gc)
PRESTWICK_294
nsc177023
tramisol
C07906
levamisole hydrochloride
16595-80-5
ergamisol (tn) (janssen)
r 12,564
niratic hydrochloride
lev hydrochloride
tramisole
imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride
nsc-177023
imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, l-(-)-
imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (-)-
imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (s)-
niratic-puron hydrochloride
r 12564
l-tetramisole hydrochloride
stimamizol hydrochloride
decaris
(-)-2,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole monohydrochloride
D00750
ergamisol (tn)
levamisole hydrochloride (usp)
NCGC00094446-03
SPECTRUM1503245
NCGC00094046-01
(-)-tetramisole hydrochloride
hydrochloride, levamisole
MLS002222198
L 9756
MLS002695941
BMK1-H6
levamisole hcl
l-narpenol
chebi:6433 ,
r-12564
tetramisole hydrochloride, (s)-
CHEMBL1770
r 12654
spartakon l
levamisoli hydrochloridum
(-)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
T1215
HMS1568F05
HMS1922M11
levamisole hydrochloride [usan:usp]
imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (6s)-
unii-dl9055k809
dl9055k809 ,
L0231
dtxcid5027518
dtxsid7047518 ,
tox21_111282
(s)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride
AKOS015951350
CCG-40301
LP00690
S1939
levamisole hydrochloride [who-ip]
levamisole hydrochloride [usp-rs]
levamisole hydrochloride [mi]
levamisole hydrochloride [who-dd]
levamisole hydrochloride [ep monograph]
levamisoli hydrochloridum [who-ip latin]
levamisole hydrochloride [green book]
levamisole hydrochloride [mart.]
levamisole hydrochloride [orange book]
levamisole hydrochloride [jan]
levamisole hydrochloride [usp monograph]
HY-13666
levamisole (hydrochloride)
levamisol hydrochloride
SCHEMBL19226
tox21_111282_1
NCGC00263461-01
tox21_500690
NCGC00261375-01
LAZPBGZRMVRFKY-HNCPQSOCSA-N
(6s)-6-phenyl-2h,3h,5h,6h-imidazo[2,1-b][1,3]thiazole hydrochloride
74191-78-9
AC-23973
mfcd00012675
l(-)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
(s)-(-)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride
(6s)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole;hydrochloride
J-521642
levamisole hydrochloride, united states pharmacopeia (usp) reference standard
levamisol hydrochloride, vetranal(tm), analytical standard
levamisole hydrochloride, european pharmacopoeia (ep) reference standard
Z1550648764
levamisole hydrochloride for system suitability, european pharmacopoeia (ep) reference standard
levamisole hydrochloride 1.0 mg/ml in methanol (as free base)
J-010244
SR-01000075969-6
sr-01000075969
SR-01000075969-1
levamisole hydrochloride, pharmaceutical secondary standard; certified reference material
levamisole hydrochloride (ergamisol)
(7s)-7-phenyl-4-thia-1,6-diazabicyclo[3.3.0]oct-5-ene hydrochloride
levamisole hcl(ergamisol)
levamisole hydrochloride,(s)
Q27107205
levamisol hydrochloride 100 microg/ml in acetonitrile
AS-13370
BCP13755
((-)-tetramisole hydrochloride
EN300-122366
16595-80-5 (hcl)
D78137
(s)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazolehydrochloride
BL166245
ripercol l soluble drench powder
prohibitsoluble drench powder
levamisole hydrochloride (mart.)
levamed soluble drench powder
trimisol
ergamisole
ici-59623
ripercol l bolus, tramisol cattle wormer bolus
levasole sheep wormer bolus, tramisole sheep wormer oblets tablets
levamisole hydrochloride (usan:usp)
levasole cattle wormer bolus
levasole soluble pig wormer
levamisole hydrochloride (usp-rs)
immunol
levamisole soluble drench powder, levasole, levasole soluble drench powder, tramisol soluble drench powder
rp-20605
levamisole hydrochloride (ep monograph)
levamisole hydrochloride (usp monograph)
levamed soluble pig wormer
ripercol l wormer oblets, tramisol sheep wormer oblets
levamed
(s)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride
prohibit soluble drench powder
cloridrato de levamizol
ripercol l, tramisol soluble drench powder for sheep
tramisol gel

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID2323
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686978; AID686979
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.49710.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.97160.000229.305416,493.5996AID743075; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.01580.540617.639296.1227AID2364; AID2528
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency6.30960.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)Ki54.50000.34000.46500.5900AID453296; AID590779
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
skeletal system developmentAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
osteoblast differentiationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
endochondral ossificationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
developmental process involved in reproductionAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
cellular homeostasisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
bone mineralizationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to lipopolysaccharideAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to insulinAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to vitamin DAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to vitamin B6Alkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to macrophage colony-stimulating factorAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
pyridoxal phosphate metabolic processAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to antibioticAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to glucocorticoidAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
phosphate ion homeostasisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
calcium ion homeostasisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
cellular response to organic cyclic compoundAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
cementum mineralizationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
positive regulation of cold-induced thermogenesisAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
futile creatine cycleAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
inhibition of non-skeletal tissue mineralizationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
response to sodium phosphateAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
dephosphorylationAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
alkaline phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
inorganic diphosphate phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
calcium ion bindingAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
pyrophosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
ATP hydrolysis activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
pyridoxal phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
ADP phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
phosphoamidase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
phosphoethanolamine phosphatase activityAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
mitochondrial intermembrane spaceAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
plasma membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
mitochondrial membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular regionAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
plasma membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular matrixAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
extracellular exosomeAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
side of membraneAlkaline phosphatase, tissue-nonspecific isozymeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID453293Inhibition of bovine intestinal alkaline phosphatase assessed as residual enzyme activity at 0.1 mM in presence of 1% DMSO at pH 10.4 at 37 degC relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and evaluation of benzo[b]thiophene derivatives as inhibitors of alkaline phosphatases.
AID574279Antiparasitic activity against Ancylostoma caninum isolate PR assessed as compound concentration required to inhibit parasitic contraction by larval arrested morphology assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID453296Inhibition of human tissue non-specific alkaline phosphatase at pH 9.82009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and evaluation of benzo[b]thiophene derivatives as inhibitors of alkaline phosphatases.
AID574288Ratio of EC50 for Ancylostoma caninum isolate PR to IC50 for Ancylostoma caninum isolate NT by by force transduction assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID453297Inhibition of chicken tissue non-specific alkaline phosphatase at pH 9.82009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and evaluation of benzo[b]thiophene derivatives as inhibitors of alkaline phosphatases.
AID574287Antiparasitic activity against Ancylostoma caninum isolate PR assessed as concentration of drug required to cause a force of contraction half that of the KCl-induced maximal contraction by force transduction assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574280Ratio of IC50 for Ancylostoma caninum isolate NT to IC50 for Ancylostoma caninum isolate PR by larval arrested morphology assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574286Antiparasitic activity against Ancylostoma caninum isolate NT assessed as concentration of drug required to cause a force of contraction half that of the KCl-induced maximal contraction by force transduction assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574278Antiparasitic activity against Ancylostoma caninum isolate NT assessed as compound concentration required to inhibit parasitic contraction by larval arrested morphology assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID453295Inhibition of porcine kidney tissue non-specific alkaline phosphatase at pH 7.8 at 37 degC2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and evaluation of benzo[b]thiophene derivatives as inhibitors of alkaline phosphatases.
AID590779Inhibition of recombinant TNAP2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of thiophenyl derivatives as inhibitors of alkaline phosphatase.
AID453294Inhibition of porcine kidney tissue non-specific alkaline phosphatase assessed as residual enzyme activity at 0.4 mM in presence of 1% DMSO at pH 10.4 at 37 degC relative to untreated control2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and evaluation of benzo[b]thiophene derivatives as inhibitors of alkaline phosphatases.
AID574282Antiparasitic activity against Ancylostoma caninum isolate PR assessed as compound concentration required to inhibit parasitic contraction by larval motility assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID590780Inhibition of pig TNAP at pH 10.4 by UV-visible spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of thiophenyl derivatives as inhibitors of alkaline phosphatase.
AID574281Antiparasitic activity against Ancylostoma caninum isolate NT assessed as compound concentration required to inhibit parasitic contraction by larval motility assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574283Ratio of IC50 for Ancylostoma caninum isolate NT to IC50 for Ancylostoma caninum isolate PR by larval motility assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID590781Inhibition of pig TNAP at pH 7.8 by UV-visible spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of thiophenyl derivatives as inhibitors of alkaline phosphatase.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (12.50)29.6817
2010's14 (58.33)24.3611
2020's7 (29.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.76 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index98.29 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (45.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]